Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Cogent Biosciences (COGT) has reported Current Deferred Revenue for 4 consecutive years, with $312000.0 the latest figure, recorded in Q2 2020.

• In Q2 2020, Current Deferred Revenue fell 97.95% year-over-year to $312000.0; the TTM figure through Jun 2020 stood at $312000.0 (down 97.95% YoY), while the FY2019 annual figure was $1.3 million, down 92.67% from the prior year.
• Current Deferred Revenue retreated to $312000.0 in Q2 2020 per COGT's latest filing, from $841000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $20.4 million in Q2 2018 and bottomed at $312000.0 in Q2 2020.
• Historically, Current Deferred Revenue has averaged $12.0 million across 4 years, with a median of $15.2 million in 2019.
• Annual changes were most pronounced in 2018 — Current Deferred Revenue soared 160.47% — and 2020, when it slumped 97.95%.
• Cogent Biosciences' Current Deferred Revenue stood at $6.9 million in 2017, then jumped by 160.47% to $17.9 million in 2018, then sank by 92.67% to $1.3 million in 2019, then sank by 76.27% to $312000.0 in 2020.
• Business Quant data shows COGT's Current Deferred Revenue at $312000.0 in Q2 2020, $841000.0 in Q1 2020, and $1.3 million in Q4 2019.